Replies to post #222544 on Biotech Values

[DewDiligence]

RVNC's 2018 YTD—(i.e. 9-month)—pro forma cash burn has been just under $100M, if you exclude the $25M up-front payment received from MYL for the Botox-biosimilar collaboration:

#msg-144654901 9/30/18
#msg-139013481 12/31/17